LONDON – After failing to reach the primary endpoint in a 507-patient phase IIb trial in acute coronary syndrome (ACS), Cerenis Therapeutics SA has found a route forward for its CER-001 recombinant high-density lipoprotein (HDL), securing orphan drug status in two variants of an inherited rare disorder that causes HDL deficiency.